- Home
- BME vs FULC Comparison
BME vs FULC Comparison
Compare BME & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BME | FULC |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 534.8M | 468.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | BME | FULC |
|---|---|---|
| Price | $42.02 | $10.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 34.0K | ★ 911.2K |
| Earning Date | 01-01-0001 | 02-24-2026 |
| Dividend Yield | ★ 6.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.37 | ★ N/A |
| Revenue Growth | N/A | ★ 2752.05 |
| 52 Week Low | $35.53 | $2.32 |
| 52 Week High | $43.20 | $15.74 |
Technical Indicators
Market Signals| Indicator | BME | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 65.05 | 45.58 |
| Support Level | $41.58 | $9.07 |
| Resistance Level | $42.35 | $10.50 |
| Average True Range (ATR) | 0.44 | 0.73 |
| MACD | 0.02 | -0.21 |
| Stochastic Oscillator | 85.11 | 39.60 |
Price Performance
Historical ComparisonAbout BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.